RxDoctor Payments Data

Robert Rinkenberger, MD

Clinical Cardiac Electrophysiology · Plano, TXNPI 1194769133

Payments from drug & device makers

$475in general payments, 2019–2025

Across 19 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$172
  • Sanofi-aventis U.S. LLC$168
  • Novartis$69
  • Convatec Inc.$26
  • Medicomp Inc$16
  • Boehringer Ingelheim$15
  • plus $10 from 1 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific3$172
Sanofi-aventis U.S. LLC9$168
Novartis3$69
Convatec Inc.1$26
Medicomp Inc1$16
Boehringer Ingelheim1$15
Infobionic, Inc1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475 in reported general payments places this provider in the 0th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$104,546
Medicare patients
2,268
Services billed
4,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$54,328
MultaqDronedarone Hcl27$30,526
XareltoRivaroxaban28$26,732
EntrestoSacubitril/Valsartan18$23,900
SymbicortBudesonide/Formoterol Fumarate11$2,626
Metoprolol Succinate44$891
SotalolSotalol Hcl26$597
Digoxin22$593
Alprazolam23$527
Flecainide Acetate15$489
Verapamil ErVerapamil Hcl11$343
Amiodarone Hcl18$199
Carvedilol23$172
Furosemide26$170
Atorvastatin Calcium20$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$168$30,52627 claims
NovartisEntresto$69$23,90018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →